Fever and Increased Gastrointestinal Uptake on Positron Emission Tomography after Anti-Tumour Necrosis Factor Therapy: A Case Report of Whipple’s Disease

Authors: Arteen Arzivian, Brett Jones, Fredrick Joshua, Miriam Paul, Thomas Lynch, Martin Brown, Robin Gasiorowski

Source: Case Reports in Gastroenterology, Vol 18, Iss 1, Pp 221-230 (2024)

Subject Terms: whipple’s disease, tropheryma whipplei, arthritis, anti-tumour necrosis factor, case report, Diseases of the digestive system. Gastroenterology, RC799-869

File Description: electronic resource

Relation: https://beta.karger.com/Article/FullText/538462; https://doaj.org/toc/1662-0631

Access URL: https://doaj.org/article/1fed07e14ca84d71893f28f11a6ddcba

Systemic lupus erythematosus induced by anti-tumor necrosis factor α therapy in inflammatory rheumatic diseases: a case series

Authors: D. Oliveira, A. Martins, F. Martins, C. Gomes, S. Pimenta, C. Vaz, L. Costa, M. Bernardes

Source: Reumatismo (2024)

Subject Terms: Systemic lupus erythematosus, anti-tumour necrosis factor alpha therapy, rheumatoid arthritis, spondylarthritis, psoriatic arthritis, Medicine, Internal medicine, RC31-1245

File Description: electronic resource

Relation: https://www.reumatismo.org/reuma/article/view/1658; https://doaj.org/toc/0048-7449; https://doaj.org/toc/2240-2683

Access URL: https://doaj.org/article/267684fb9ff74a6cb1d163f5ce8bbdb0

Cytokines and regulatory T cells in ankylosing spondylitis

Authors: Hsien-Tzung Liao, Chang-Youh Tsai

Source: Bone & Joint Research, Vol 12, Iss 2, Pp 133-137 (2023)

Subject Terms: cytokine, regulatory t cell, ankylosing spondylitis, anti-tumour necrosis factor-α, ankylosing spondylitis (as), cytokines, inflammatory cytokines, il-10, serum, mononuclear cells, interleukin, crp, blood, anti-tumour necrosis factor, Diseases of the musculoskeletal system, RC925-935

File Description: electronic resource

Relation: https://doaj.org/toc/2046-3758

Access URL: https://doaj.org/article/1081b5f7b7474ca7ba21c1fe0d6cdf5e

Cost-effectiveness of adalimumab for early-stage Dupuytren’s disease an economic evaluation based on a randomized controlled trial and individual-patient simulation model

Authors: Helen Dakin, Ines Rombach, Melina Dritsaki, Alastair Gray, Catherine Ball, Sarah E. Lamb, Jagdeep Nanchahal

Source: Bone & Joint Open, Vol 3, Iss 11, Pp 898-906 (2022)

Subject Terms: Adalimumab, Anti-tumour necrosis factor, Cost-effectiveness analysis, Economic evaluation, Dupuytren’s disease, Palmar fibromatosis, Orthopedic surgery, RD701-811

File Description: electronic resource

Relation: https://doaj.org/toc/2633-1462

Access URL: https://doaj.org/article/76adb041d89d4c2e9bbfef39e6f55481

Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with behçet’s disease: A systematic review of controlled trials

Authors: Xinwei Zhou, Xianghui Shi, Yanxia Ren, Tingting Yan, Qiao Ye

Source: Frontiers in Pharmacology, Vol 13 (2022)

Subject Terms: anti-tumour necrosis factor-alpha, uveitis, behçet disease, systematic review, control trials, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2022.912906/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/6fb31a324846457099acfed033041143

Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care Setting

Authors: Adriaan Volkers, Mark Löwenberg, Marlou Braad, Yara Abeling, Krisztina Gecse, Nicole Berkers, Nahid Montazeri, Geert D’Haens

Source: Diagnostics, Vol 13, Iss 10, p 1712 (2023)

Subject Terms: point-of care, inflammatory bowel diseases, follow-up, anti-tumour necrosis factor, biomarkers, Crohn’s disease, Medicine (General), R5-920

File Description: electronic resource

Relation: https://www.mdpi.com/2075-4418/13/10/1712; https://doaj.org/toc/2075-4418

Access URL: https://doaj.org/article/e6448056111e4d56bdf6bcebc9eaf899

Testicular ischemia in deficiency of adenosine deaminase 2 (DADA2)

Authors: Katherine Clarke, Cathy Campbell, Ebun Omoyinmi, Ying Hong, Muthana Al Obaidi, Neil Sebire, Paul A. Brogan

Source: Pediatric Rheumatology Online Journal, Vol 17, Iss 1, Pp 1-7 (2019)

Subject Terms: Deficiency of adenosine deaminase 2, DADA2, Testicular infarction, Vasculitis, Anti-tumour necrosis factor alpha, Aspirin, Pediatrics, RJ1-570, Diseases of the musculoskeletal system, RC925-935

File Description: electronic resource

Relation: http://link.springer.com/article/10.1186/s12969-019-0334-5; https://doaj.org/toc/1546-0096

Access URL: https://doaj.org/article/9442f811f3af4c4a9cbe47c23e0517ec

Allergic bronchopulmonary aspergillosis in a patient with ankylosing spondylitis treated with adalimumab

Authors: Yudai Suzuki, Naoki Takasaka, Sachi Matsubayashi, Ayako Kojima, Kyota Shinfuku, Tsukasa Hasegawa, Masami Yamada, Ikumi Fujisaki, Aya Seki, Yoshitaka Seki, Takeo Ishikawa, Kazuyoshi Kuwano

Source: Respirology Case Reports, Vol 9, Iss 8, Pp n/a-n/a (2021)

Subject Terms: Adalimumab, allergic bronchopulmonary aspergillosis, ankylosing spondylitis, anti‐tumour necrosis factor‐α antibody, Diseases of the respiratory system, RC705-779

File Description: electronic resource

Relation: https://doaj.org/toc/2051-3380

Access URL: https://doaj.org/article/a3739e1bf5434725bdc9de241fcc17e6

Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis

Authors: Boris Gole, Uroš Potočnik

Source: Cells, Vol 8, Iss 6, p 515 (2019)

Subject Terms: Crohn’s disease, inflammatory bowel disease, anti-tumour necrosis factor, adalimumab, infliximab, certolizumab pegol, therapy response, biomarker, Cytology, QH573-671

File Description: electronic resource

Relation: https://www.mdpi.com/2073-4409/8/6/515; https://doaj.org/toc/2073-4409

Access URL: https://doaj.org/article/5073457b272f481da4df78ef421a0405

A Review of Crohn’s Disease

Authors: Philip Hendy, Ailsa Hart

Source: European Medical Journal Gastroenterology, Vol 2, Iss 1, Pp 116-123 (2013)

Subject Terms: Anti-tumour Necrosis Factor Alpha (anti–TNFα), Autophagy Genes, Crohn’s Disease, Immunomodulators, Inflammatory Bowel Disease, Metabolomics, Metagenomics, NOD2, Diseases of the digestive system. Gastroenterology, RC799-869

File Description: electronic resource

Relation: http://emjreviews.com/wp-content/uploads/A-Review-of-Crohn%E2%80%99s-Disease.pdf; https://doaj.org/toc/2054-6203

Access URL: https://doaj.org/article/6968d92f0c954488967687fd3e00d0fe

Disseminated Nocardia infection: spontaneous resolution in response to decrease of immunosuppression

Authors: K. van Dijk, D.A. van Kessel, M.J. Schijffelen, W.R. Staartjes, M. Tersmette

Source: New Microbes and New Infections, Vol 3, Iss C, Pp 10-11 (2015)

Subject Terms: Anti-tumour necrosis factor-α, Immunosuppression, Nocardia, Rheumatoid arthritis, Spontaneous resolution, Infectious and parasitic diseases, RC109-216

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S205229751400002X; https://doaj.org/toc/2052-2975

Access URL: https://doaj.org/article/7130e762faa3474badffed9f16a13413

Current treatment for prevention of relapse and recurrence in Crohn's disease
The use of a novel anti-tumour necrosis factor ALPHA (Infliximab, Remicade[TM]): a new strategy for medical treatment of Crohn's disease

Authors: Prantera, C., Scribano, M. L.

Source: ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 31(6):515-518

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN032164685&indx=1&recIds=ETOCCN032164685

Current treatment modalities in active Crohn's disease
The use of a novel anti-tumour necrosis factor ALPHA (Infliximab, Remicade[TM]): a new strategy for medical treatment of Crohn's disease

Authors: Biancone, L., Pallone, F.

Source: ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 31(6):508-514

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN032164670&indx=1&recIds=ETOCCN032164670

Epidemiology of inflammatory bowel disease in Italy
The use of a novel anti-tumour necrosis factor ALPHA (Infliximab, Remicade[TM]): a new strategy for medical treatment of Crohn's disease

Authors: Cottone, M., Martorana, G., Di Mitri, R., Camma, C.

Source: ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 31(6):503-507

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN032164664&indx=1&recIds=ETOCCN032164664

Infliximab (Remicade[TM]), a new biological treatment for Crohn's disease
The use of a novel anti-tumour necrosis factor ALPHA (Infliximab, Remicade[TM]): a new strategy for medical treatment of Crohn's disease

Authors: D'Haens, G. R.

Source: ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. 31(6):519-520

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN032164690&indx=1&recIds=ETOCCN032164690

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.